InvestorsHub Logo
Followers 80
Posts 24703
Boards Moderated 1
Alias Born 09/08/2000

Re: None

Monday, 06/19/2017 8:21:17 AM

Monday, June 19, 2017 8:21:17 AM

Post# of 27622
RIGL - 2.50 Pre-market at 2.82/2.83

FDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP



Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.